Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline embolization device

Journal of NeuroInterventional Surgery

Volumn 7, Issue 6, 2015, Pages 425-430

  McTaggart, Ryan A ^a,b   Choudhri, Omar A ^c   Marcellus, Mary L ^c   Brennan, Tom ^c   Steinberg, Gary K ^c   Dodd, Robert L ^c   Do, Huy M ^c   Marks, Michael P ^c  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; ARTIFICIAL EMBOLISM; BLEEDING; BLOOD CLOTTING PARAMETERS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; CRANIAL NERVE PARALYSIS; FEMALE; FOLLOW UP; HEMOPTYSIS; HUMAN; INTRACRANIAL ANEURYSM; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PIPELINE EMBOLIZATION DEVICE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD VESSEL PROSTHESIS; DEVICES; DRUG COMBINATION; EVALUATION STUDY; MIDDLE AGED; PROCEDURES; STANDARDS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD VESSEL PROSTHESIS; DRUG THERAPY, COMBINATION; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRACRANIAL ANEURYSM; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THROMBELASTOGRAPHY; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84929318129     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2013-011089     Document Type: Article

References (21)

1. Administration. USFaD. Pipeline Embolization Device-P100018: Summary of safety and effectiveness data (SSED).
2. Becske T, Kallmes DF, Saatci I, et al. Pipeline for uncoilable or failed aneurysms: Results from a multicenter clinical trial. Radiology 2013; 267: 858-68.
3. Chalouhi N, Tjoumakaris S, Dumont AS, et al. Treatment of posterior circulation aneurysms with the pipeline embolization device. Neurosurgery 2013; 72: 883-9.
4. Jabbour P, Chalouhi N, Tjoumakaris S, et al. The pipeline embolization device: Learning curve and predictors of complications and aneurysm obliteration. Neurosurgery 2013; 73: 113-20.
5. Phillips TJ, Wenderoth JD, Phatouros CC, et al. Safety of the pipeline embolization device in treatment of posterior circulation aneurysms. AJNR Am J Neuroradiol 2012; 33: 1225-31.
6. Pistocchi S, Blanc R, Bartolini B, et al. Flow diverters at and beyond the level of the circle of willis for the treatment of intracranial aneurysms. Stroke 2012; 43: 1032-8.
7. Saatci I, Yavuz K, Ozer C, et al. Treatment of intracranial aneurysms using the pipeline flow-diverter embolization device: A single-center experience with long-term follow-up results. AJNR Am J Neuroradiol 2012; 33: 1436-46.
8. Yu SC, Kwok CK, Cheng PW, et al. Intracranial aneurysms: Midterm outcome of pipeline embolization device-a prospective study in 143 patients with 178 aneurysms. Radiology 2012; 265: 893-901.
9. Delgado Almandoz JE, Crandall BM, Scholz JM, et al. Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline embolization device. J Neurointerv Surg 2013; 5 (Suppl 3): Iii3-10.
10. Cattano D, Altamirano AV, Kaynak HE, et al. Perioperative assessment of platelet function by thromboelastograph platelet mapping in cardiovascular patients undergoing non-cardiac surgery. J Thromb Thrombolysis 2013; 35: 23-30.
11. MacIvor D, Rebel A, Hassan ZU. How do we integrate thromboelastography with perioperative transfusion management? Transfusion 2013; 53: 1386-92.
12. Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-66.
13. Gurbel PA, Bliden KP, Navickas IA, et al. Adenosine diphosphate-induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010; 160: 346-54.
14. McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100: 1576-83.
15. Aradi D, Storey RF, Komocsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart J 2014; 35: 209-15.
16. Janssen PW, ten Berg JM. Platelet function testing and tailored antiplatelet therapy. J Cardiovasc Transl Res 2013; 6: 316-28.
17. Comin J, Kallmes DF. Platelet-function testing in patients undergoing neurovascular procedures: Caught between a rock and a hard place. AJNR Am J Neuroradiol 2013; 34: 730-4.
18. Fifi JT, Brockington C, Narang J, et al. Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013; 34: 716-20.
19. Goh C, Churilov L, Mitchell P, et al. Clopidogrel hyper-response and bleeding risk in neurointerventional procedures. AJNR Am J Neuroradiol 2013; 34: 721-6.
20. Muller-Schunk S, Linn J, Peters N, et al. Monitoring of clopidogrel-related platelet inhibition: Correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008; 29: 786-91.
21. Harrison P, Lordkipanidze M. Testing platelet function. Hematol/Oncol Clin North Am 2013; 27: 411-41.